Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$11.99 USD

11.99
4,400,799

+0.03 (0.25%)

Updated Aug 23, 2024 03:59 PM ET

After-Market: $11.96 -0.03 (-0.25%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Biotech Stock Roundup: GERN Surges on Study Data, PHAT, VERA Offer Updates & More

Updates from Geron (GERN) and VERA are the key highlights from the biotech sector during the past week.

Novavax (NVAX) Starts A New Study on COVID-Flu Combo Jab

Novavax (NVAX) initiates a mid-stage study evaluating its COVID-19-Influenza combination and standalone influenza vaccines in adults aged 50 through 80 years.

Company News for Dec 16, 2022

Companies in The News Are: NFLX,WBD,NVAX,META

Pfizer (PFE), BNTX's COVID-Flu Combo Jab Gets FDA Fast Track Tag

The FDA grants fast-track designation to Pfizer (PFE)/BioNTech's (BNTX) early-stage combination vaccine candidate, which targets two respiratory diseases - influenza and COVID-19.

Novavax (NVAX) Down 7.6% Since Last Earnings Report: Can It Rebound?

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Novavax (NVAX) COVID Jab Gets Expanded Label in WHO's EUL

The WHO updates Emergency Use Listing (EUL) for Novavax's (NVAX) COVID-19 vaccine to include its use as a primary series in adolescents and for use as a booster dose in adults.

Do Options Traders Know Something About Novavax (NVAX) Stock We Don't?

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

Novavax (NVAX) Stock Nosedives 88% This Year: Here's Why

Novavax (NVAX) drops to record lows as the delayed product launch of its COVID-19 vaccine made it lose market share. Management slashes revenue guidance by more than half.

Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Novavax (NVAX) Cancels COVID Jab Supply Deal With GAVI

Novavax (NVAX) claims that GAVI's failure to procure its COVID vaccine doses is a reason to terminate the supply agreement. GAVI denies the company's claims and a legal battle is likely to follow.

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novavax (NVAX) Q3 Earnings Miss, Lowers '22 Sales Outlook

Novavax (NVAX) reports mixed results in second-quarter 2022. Management lowers guidance for 2022.

Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates

Novavax (NVAX) delivered earnings and revenue surprises of -197.29% and 33.15%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Guardant Health (GH) Reports Q3 Loss, Lags Revenue Estimates

Guardant Health (GH) delivered earnings and revenue surprises of -24.41% and 0.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $20.17, marking a -1.61% move from the previous day.

Earnings Preview: Qiagen (QGEN) Q3 Earnings Expected to Decline

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Novavax (NVAX) to Report Q3 Results: Wall Street Expects Earnings Growth

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Novavax (NVAX) Gains As Market Dips: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $22.81, marking a +1.02% move from the previous day.

Novavax (NVAX) to Report Q3 Earnings: What's in the Cards?

On Novavax's (NVAX) third-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.

Company News for Oct 21, 2022

Companies in The News Are: TSLA, T, ABB, MRNA, NVAX

Novavax (NVAX) Receives FDA Nod for COVID-19 Booster Jab

Novavax (NVAX) gets FDA authorization for using its COVID vaccine as a booster dose in adults after six months of completing the primary vaccine regimen.

Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More

Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week.

Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Novavax (NVAX) Reports Positive Data on COVID/FLU Combo Jab Study

Novavax (NVAX) reports positive data from its phase I/II study evaluating a combination of its COVID-19 and the seasonal influenza vaccine.